SCHEMBL10094406

SCHEMBL10094406

CC(=O)Nc1cccc(-c2cc(F)ccc2C(C)C)c1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SMN1; SMN2 Q16637 4/20 0.49
▸ GAA P10253 3/20 0.49
▸ NQO2 P16083 2/20 0.49
▸ BRD4 O60885 1/20 0.47
▸ ALDH1A1 P00352 3/20 0.47
▸ MAPT P10636 3/20 0.47
▸ L3MBTL1 Q9Y468 2/20 0.47
▸ KDM4E B2RXH2 1/20 0.47
▸ PKM P14618 1/20 0.47
▸ MAPK1 P28482 1/20 0.47
▸ CNR1 P21554 1/20 0.45
▸ CYP1A2 P05177 1/20 0.44
▸ HSD17B10 Q99714 1/20 0.44
▸ NPC1 O15118 1/20 0.44
▸ TSHR P16473 1/20 0.44
▸ RAB9A P51151 1/20 0.44
▸ AHR P35869 1/20 0.43
▸ RECQL P46063 1/20 0.43
▸ ATM Q13315 1/20 0.43
▸ HSD17B1 P14061 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10094401 0.85 SMN1; SMN2 (0.50) SMN1; SMN2GAABRD4ALDH1A1MAPT
SCHEMBL10094419 0.79 KCNH2 (0.53) SMN1; SMN2BRD4ALDH1A1MAPTKDM4E
SCHEMBL10094517 0.76 PARP1 (0.53) BRD4NPC1RAB9A
SCHEMBL10094403 0.76 PARP14 (0.53) SMN1; SMN2GAAALDH1A1KDM4ECYP1A2
SCHEMBL687148 0.75 GAA (0.68) SMN1; SMN2GAAALDH1A1MAPTL3MBTL1
SCHEMBL29493316 0.75 GAA (0.68) SMN1; SMN2GAAALDH1A1MAPTL3MBTL1
SCHEMBL10094400 0.74 ACHE (0.47) SMN1; SMN2NPC1RAB9A
SCHEMBL10094443 0.74 KCNA5 (0.51) BRD4
SCHEMBL23419417 0.73 PTGS1 (0.39) MAPTCYP1A2TSHRRECQL
Hydrochloric Acid SCHEMBL29536454 0.73 GAA (0.66) SMN1; SMN2GAAALDH1A1MAPTL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8148535-B2 Potassium channel inhibitors MERCK SHARP & DOHME CORP. (US) 2012-04-03 — — US disclosed
US-20090233897-A1 Potassium Channel Inhibitors MERCK SHARP & DOHME CORP. 2009-09-17 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090233897-A1 Potassium Channel Inhibitors KCNJ2, KCNQ2, KCNH2 SMN1; SMN2 4477/4885GAA 3707/4885NQO2 370/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback